Table 2.
mRNA expression of different genes involved in de novo lipogenesis in human visceral adipose tissue
Non-obese subjects (N = 15) |
MO-low-IR subjects (N = 15) |
MO-high-IR subjects (N = 15) |
|
---|---|---|---|
SIRT3 | 0.029 ± 0.014 | 0.021 ± 0.015 | 0.009 ± 0.006a* |
PDHB | 0.460 ± 0.170 | 0.244 ± 0.066a | 0.248 ± 0.081a |
ACC1 | 1.87 ± 0.43 | 1.15 ± 0.52a | 0.91 ± 0.59a |
ACSS2 | 1.14 ± 0.29 | 0.78 ± 0.42a | 0.80 ± 0.39a |
ACLY | 1.01 ± 0.79 | 0.42 ± 0.08a | 0.31 ± 0.06a |
PPARγ | 1.12 ± 0.65 | 2.72 ± 1.89a | 2.51 ± 0.87a |
SREBP-1c | 0.271 ± 0.172 | 0.131 ± 0.072a | 0.116 ± 0.067a |
FASN | 0.285 ± 0.088 | 0.148 ± 0.040a | 0.124 ± 0.020a |
MO-low-IR morbidly obese subjects with low insulin resistance, MO-high-IR morbidly obese subjects with high insulin resistance
aP < 0.05 significant differences with respect to the non-obese group
* P < 0.05 significant differences between morbidly obese patients with low and high insulin resistance. All significant differences are adjusted for sex